Abstract:PROTACs (Proteolysis Targeting Chimeras), heterobifunctional molecules, exhibit selectivity in degrading target proteins through E3 ubiquitin ligases. Designing effective PROTACs requires a deep understanding of the intricate binding interactions in the ternary complex (POI/PROTAC/E3 ligase), crucial for efficient target protein degradation. To address this challenge, we introduce a novel computational virtual screening method that considers essential amino acid interactions between the protein of interest and the chosen E3 ligase. This approach enhances accuracy and reliability, facilitating the strategic development of potent PROTACs. Utilizing a crystallized model of the VHL:PROTAC:SMARCA2BD ternary complex (PDB: 7Z6L), we assessed the effectiveness of our method. Our study reveals that increasing the number of essential restraints between the two proteins reduces the generated docking poses, leading to closer alignment with the experimental ternary complex. Specifically, utilizing three restraints showed the closest resemblance to the published complex, highlighting crucial interactions such as an H-bond between A:Gln 89 and B:Asn 67, along with two hydrophobic interactions: A:Gly 22 with B:Arg 69 and A:Glu 37 with B:Pro 99. This resulted in a significant decrease in the mean RMSD value from 31.8 and 31.0 Å to 24.4 Å, respectively. This underscores the importance of incorporating multiple essential restraints to enhance docking accuracy. Building on this progress, we introduce a systematic approach to design potential PROTACs between the Estrogen receptor and the E3 ligase, utilizing bridging intermediates with 4, 6, or 7 carbon atoms. By providing a more accurate and efficient means of identifying optimal PROTAC candidates, this approach has the potential to accelerate the development of targeted therapies and reduce the time and costs associated with drug discovery.Communicated by Ramaswamy H. Sarma.

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

E3 ligase ligand optimization of Clinical PROTACs

A One-Pot Photocatalytic Triazole-Based Linkerology for PROTACs

Current Advances of Small Molecule E3 Ligands for Proteolysis-Targeting Chimeras Design

The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation

PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Discovery of E3 Ligase Ligands for Target Protein Degradation

Computation, Synthesis and NMR Investigations of PROTAC Linker Conformation, Chamaleonicity and their Impacts on the Mode of Action

Clinical considerations for the design of PROTACs in cancer

Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)

Targeted protein degradation: expanding the toolbox

An overview of PROTACs: a promising drug discovery paradigm

A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase‐based Partial PROTAC Library

Characteristic roadmap of linker governs the rational design of PROTACs

Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

A close-up shot of protein-protein docking, from experiment to theory and reverse with the PROTAC performers